Scarica l'app Stockscreener
0.5342
1.29%
-0.007
Longeveron Inc Borsa (LGVN) Ultime notizie
How cyclical is Longeveron Incs revenue streamEarnings Growth Summary & Weekly High Conviction Trade Ideas - baoquankhu1.vn
Longeveron Applauds Passage of the Mikaela Naylon Give Kids a Chance Act and Reauthorization of Rare Pediatric Disease Priority Review Voucher Program - The Manila Times
Congress renews voucher that may speed Longeveron heart therapy for babies - Stock Titan
Merger Talk: Is WABC part of any major indexVolume Spike & Advanced Swing Trade Entry Alerts - baoquankhu1.vn
Market Catalysts: Will Longeveron Inc benefit from rising consumer demand2025 Earnings Surprises & Weekly Top Gainers Trade List - baoquankhu1.vn
Longeveron receives Japanese patent for stem cell potency assay methods By Investing.com - Investing.com South Africa
Longeveron receives Japanese patent for stem cell potency assay methods - Investing.com
Longeveron® Granted Japan Patent for Potency Assay Methods for Assessing Human Mesenchymal Stem Cells (MSCs) - The Manila Times
Longeveron prepares for pivotal HLHS therapy data with FDA meeting By Investing.com - Investing.com Nigeria
Gainers Report: Whats the outlook for CrowdStrike Holdings Incs sectorTake Profit & Growth Focused Stock Reports - baoquankhu1.vn
Published on: 2026-01-27 00:29:51 - baoquankhu1.vn
Longeveron Granted FDA Type C Meeting Ahead Of Pivotal ELPIS II Data For HLHS - Nasdaq
Longeveron prepares for pivotal HLHS therapy data with FDA meeting - Investing.com
Longeveron Announces FDA Grants Type C Meeting Ahead of Data Readout for Pivotal Phase 2 Clinical Trial (ELPIS II) Evaluating Treatment for Hypoplastic Left Heart Syndrome (HLHS) - The Manila Times
Stem cell therapy for rare infant heart defect moves into key FDA talks - Stock Titan
Aug Big Picture: Is Longeveron Inc exposed to political riskJuly 2025 Sector Moves & Expert-Curated Trade Recommendations - baoquankhu1.vn
Revenue Check: What is Longeveron Incs revenue forecastQuarterly Trade Report & Long-Term Capital Growth Ideas - baoquankhu1.vn
Buyback Watch: What is the implied volatility of Telefnica Brasil SA Depositary ReceiptJuly 2025 Levels & Real-Time Price Movement Reports - baoquankhu1.vn
Portfolio Recap: Can Longeveron Inc continue delivering strong returnsQuarterly Portfolio Review & Comprehensive Market Scan Insights - baoquankhu1.vn
Surprises Report: Is Longeveron Inc stock a defensive play in 2025Quarterly Market Review & AI Powered Buy and Sell Recommendations - Bộ Nội Vụ
Options Flow: Is Longeveron Inc stock a top momentum play2025 Technical Overview & Free Real-Time Market Sentiment Alerts - Bộ Nội Vụ
Can Longeveron Inc. stock attract ESG capital inflowsJuly 2025 Technicals & Consistent Profit Trade Alerts - Улправда
Is Longeveron Inc. stock positioned for long term growthEarnings Growth Report & Daily Price Action Insights - ulpravda.ru
Why Longeveron Inc. stock is considered a top pickJuly 2025 Volume & Consistent Return Strategy Ideas - ulpravda.ru
Will Longeveron Inc. stock continue upward momentumQuarterly Trade Review & Technical Pattern Alert System - Улправда
Is Longeveron Inc. stock a top momentum play2025 Market Overview & Long-Term Investment Growth Plans - Улправда
Rockford Register Star: Local News, Politics & Sports in Rockford, IL - FinancialContent
Longeveron Inc.Class A Common stock (NQ: LGVN - FinancialContent
Longeveron Shares Jump as FDA Clears Phase 2 Trial for Pediatric Heart Therapy - MSN
Longeveron, Selected as a StartUp Health Alzheimer’s Disease Moonshot Company, Will Participate in StartUp Health Apollo House During JPM Healthcare Week 2026 - marketscreener.com
Alzheimer’s ‘moonshot’ network taps Longeveron to join 2026 founder summit - Stock Titan
Longeveron (NASDAQ:LGVN) Stock Price Down 3.2% – What’s Next? - Defense World
Will Longeveron Inc. stock attract more institutional investors2025 Market WrapUp & Weekly High Conviction Trade Ideas - Улправда
Is Longeveron Stock Built to Withstand More Downside? - Trefis
Comparing Longeveron (NASDAQ:LGVN) & Senti Biosciences (NASDAQ:SNTI) - Defense World
What drives Longeveron Inc stock priceDouble Top/Bottom Patterns & Trusted Financial Advisors at No Cost - earlytimes.in
Longeveron Earnings Notes - Trefis
Is Longeveron Inc. stock a good choice for value investorsNew Guidance & Verified Stock Trade Ideas - Улправда
What risks investors should watch in Longeveron Inc. stockPortfolio Return Summary & Comprehensive Market Scan Reports - DonanımHaber
Why Longeveron Inc. stock remains on watchlists2025 Valuation Update & Technical Confirmation Trade Alerts - DonanımHaber
Is Longeveron Inc. stock a buy in volatile marketsEarnings Trend Report & Precise Swing Trade Alerts - ulpravda.ru
What technical signals suggest for Longeveron Inc. stockEarnings Summary Report & Fast Moving Stock Trade Plans - Улправда
Longeveron receives patent for stem cell therapy targeting female sexual dysfunction - Investing.com Canada
Longeveron granted U.S. patent for method of treating female sexual dysfunction - marketscreener.com
Longeveron receives patent for stem cell therapy targeting female sexual dysfunction By Investing.com - Investing.com South Africa
Longeveron Granted U.S. Patent for Method of Treating Female Sexual Dysfunction Using its Proprietary Stem Cell Therapy - The Manila Times
Block Trades: What risks investors should watch in Longeveron Inc stockRate Cut & Free High Return Stock Watch Alerts - moha.gov.vn
Beyond Weight Loss: The "Cellular Reset" That Could Create the Next Biotech Supercycle - The Globe and Mail
Longeveron granted Canadian patent covering laromestrocel administration - MSN
Longeveron launches offering of up to 11.8M shares via warrants and stock units - MSN
Prepare Yourself for Liftoff: Longeveron Inc (LGVN) - Setenews
With Longeveron Stock Sliding, Have You Assessed The Risk? - Trefis
Update Recap: Can MCK stock sustain institutional flowsWatch List & Free Weekly Watchlist of Top Performers - BỘ NỘI VỤ
Longeveron executives to speak at CVCT Forum on cell therapy trials - Investing.com Nigeria
1.24%
0.19%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):